Amarin stock tanks nearly 70% after losing a patent battle over its key heart drug (AMRN)

· *The United States District Court of Nevada on Monday ruled that Amarin's patent claims for Vascepa, a heart drug that uses fish oil to lower triglycerides, are invalid, potentially giving generic drugmakers the opportunity to knock off the treatment. *
· *Shares of Amarin shed nearly 70% Tuesday on the news. *
·...